Additional Relevant Details Dermira now expects to announce topline efficacy and safety data for both of these trials during the second quarter of 2016, compared with previous guidance of mid-2016.
“Once again, we are delighted to announce the completion of patient enrollment, ahead of schedule, in a Dermira clinical program, this time for our two Phase 3 DRM04 pivotal clinical trials in hyperhidrosis,” stated Luis Peña, chief development officer of Dermira.  “We continue to believe that DRM04, a topically administered anticholinergic, may provide an attractive therapeutic approach, if approved, relative to the currently available treatment options for patients suffering from hyperhidrosis. We look forward to sharing the results from our Phase 3 trials in the coming months.”